From complex generics and biosimilars to specialty brands, our medicines and therapies are designed to help improve care —driven by innovation, refined through R&D, and crafted with quality.
10B
doses of medicine manufactured each year across multiple dosage forms
290+
products (generics, biologics and specialty pharmaceuticals)
Andy Boyer
Executive Vice President,
Chief Commercial Officer - Generics & Biosciences
We develop generic medicines across a range of increasingly complex product formats: oral solids and liquids, injectables, ophthalmics, topicals, softgels, inhalation products and transdermals.
Exenatide Injection
270+
generic medicines
Naloxone®
Amneal Epinephrine Auto-injector
Sean McGowan,
Senior Vice President, Biosimilars and Branded Oncology
We are a leader in U.S.-based Biosimilar development, helping increase access to large molecule therapies for more and more patients across oncology and beyond.
5 launches expected by 2027
Pipeline6+
commercial biosimilar products
Boruzu®
Learn more about the Amneal Biosciences pipeline
Joe Renda
Senior Vice President
Chief Commercial Officer- Specialty
We have a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. We work with neurologists, movement disorder specialists, endocrinologists and primary care physicians in key markets throughout the U.S. to create cutting edge Specialty products.
The first and only DHE auto-injector for the acute treatment of migraine with and without aura and cluster headaches in adults
12
specialty medicines
Unithroid®
CREXONT®
Led by a world-class team and fueled by one of the industry’s largest generics pipelines, our R&D strategies accelerate meaningful innovation and lasting value across our portfolios.
Corporate
India